AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris
April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday for allegedly misusing its patents to extend its monopoly on its blockbuster blood-disease drug Soliris.
Health plan EmblemHealth said in the proposed class action lawsuit, opens new tab that Alexion wrongly obtained new patents to block biosimilar versions of Soliris for four years after its patents on the drug should have expired.
EmblemHealth said the alleged scheme violated U.S. antitrust law and could cause overpayments of more than $2 billion for Soliris.
Spokespeople for AstraZeneca did not immediately respond to a request for comment on the complaint.
"We are concerned about practices that shut down competition and increase drug costs. That's what this litigation is about," an EmblemHealth spokesperson said.
EmblemHealth is seeking to represent a class of U.S. Soliris buyers in the lawsuit.
Soliris is used to treat rare blood disorders. AstraZeneca earned more than $1.4 billion from sales of the drug in the first half of 2024, according to a company report.
EmblemHealth said in the lawsuit that AstraZeneca charges "one of the single highest drug costs in U.S. history" for Soliris, which costs "upwards of $500,000 per patient per year."
AstraZeneca's patents covering Soliris should have expired in 2021, but the company misled the U.S. Patent and Trademark Office to obtain more patents with expiration dates "well into the future," according to the complaint. The lawsuit said AstraZeneca used the new patents to "extract settlements" from competitors and delay their biosimilars until March 2025 at the earliest.
EmblemHealth asked the court for an order ending AstraZeneca's monopoly on Soliris and an unspecified amount of monetary damages.
The case is EmblemHealth Inc v. Alexion Pharmaceuticals Inc, U.S. District Court for the District of Massachusetts, No. 1:25-cv-10985.
For EmblemHealth: Thomas Sobol and Gregory Arnold of Hagens Berman Sobol Shapiro; and Mark Fischer and Rob Griffith of Rawlings & Associates
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
3 hours ago
- Reuters
South African rand shrugs off weak manufacturing data
JOHANNESBURG, June 10 (Reuters) - The South African rand strengthened on Tuesday despite a sharp contraction in local manufacturing output, as investors waited for more clarity on U.S.-China trade talks. At 1415 GMT, the rand traded at 17.69 against the dollar , about 0.2% stronger than Monday's closing level. South Africa's manufacturing output (ZAMAN=ECI), opens new tab fell 6.3% year on year in April, the sixth consecutive monthly decline, statistics agency data showed on Tuesday. Analysts polled by Reuters had expected a drop of 3.9%. Weakness in the manufacturing sector was one factor behind the first quarter's sluggish growth of just 0.1%(ZAGDPN=ECI), opens new tab, offsetting a strong performance by agriculture. The rand was also supported on Tuesday by a stronger global gold price and by a weaker U.S. dollar . The Johannesburg Stock Exchange's Top-40 index (.JTOPI), opens new tab was last up 0.6%. The benchmark 2035 government bond was stronger, as the yield fell 4 basis points to 10.095%.
Reuters
4 hours ago
- Reuters
Kenya central bank cuts main lending rate to 9.75%
NAIROBI, June 10 (Reuters) - Kenya's central bank cut its benchmark lending rate (KECBIR=ECI), opens new tab to 9.75% on Tuesday from 10.00% previously, the bank's Monetary Policy Committee said. It was the sixth monetary policy meeting in a row that the Central Bank of Kenya has lowered the rate. "There was scope for a further easing of the monetary policy stance to augment the previous policy actions aimed at stimulating lending by banks to the private sector and supporting economic activity," the bank said in a statement. Economists polled by Reuters had been divided on what the central bank's decision would be. Out of seven forecasts three were for a cut, three for no change in the policy rate and one for a hike.
Reuters
5 hours ago
- Reuters
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
June 10 (Reuters) - Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday. Shares of AstraZeneca (AZN.L), opens new tab and BioNTech ( opens new tab were marginally up, while those of GSK (GSK.L), opens new tab and Sanofi ( opens new tab declined 1% and 0.2%, respectively. U.S. vaccine maker Moderna (MRNA.O), opens new tab fell slightly in premarket trading, while Novavax (NVAX.O), opens new tab and Pfizer (PFE.N), opens new tab traded marginally higher. Analysts said that while the unprecedented dismissals of all members of the Advisory Committee on Immunization Practices (ACIP) represented a risk for vaccine manufacturers, investors would wait to see any impact on the companies. Since he was appointed as U.S. health secretary, Kennedy, a vaccine skeptic, has made several changes to reshape the regulation of vaccines, food and medicine. However, firing members of the ACIP remains his most far-reaching move yet. Some analysts expressed concerns that the new committee members, who have not been named, might be more sympathetic to Kennedy's views on vaccines, an idea shared by scientific experts and doctors. While the makeup of a reconstituted ACIP is to be determined, "new members will likely be sympathetic to at least some of RFK's beliefs regarding alleged dangers of vaccines", Leerink analyst Daina Graybosch said in a note. Graybosch said that the move could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development. Kennedy's decision came less than three weeks before the next panel meeting set for June 25 to June 27 and is slated to discuss recommendations for who should receive vaccines for diseases like respiratory syncytial virus. It is unclear when Kennedy will announce the new members, who the agency said are under consideration, or whether the agenda will follow the meeting description posted on the Federal Register on Monday. "It's hard to assess what the ultimate impact may be on vaccine makers as we don't have much clarity on who will take these members' places on the Committee," said James Harlow, senior vice president at Novare Capital Management, which owns Pfizer shares. Harlow added that sentiment around vaccine makers has been negative coming into the news. "It would appear much has already been baked into the prices of these stocks," he said. BMO Capital Markets analyst Evan Seigerman said that RFK Jr.'s views have consistently skewed negatively to groups like ACIP, making the decision "less shocking in our eyes." Seigerman added that while the announcement introduces additional uncertainty into the sector, it likely represents "more headline risk than a true fundamental change at the agency."
